Company / Cash & Equivalents
Sunshine Biopharma Inc. Cash & Equivalents History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$21.8M
FY2022
5-year range
$2.0M / $21.8M
FY2018-FY2022
Trend
+967.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +967% YoY in FY2022, a notable deviation from the 6-year average annual change of +575%.
Based on SEC 10-K filings.
$22M in FY2022 with a 5-year CAGR of +189.4%.
Improved from $989,888 to $22M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +713.8%
- 5-Year CAGR
- +189.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +189.4%, indicating consistent growth.
- In FY2022, cash & equivalents increased 967.2% year-over-year.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $21.8M | +967.2% |
| FY2021 | $2.0M | +106.6% |
| FY2020 | $989.9K | +2344.1% |
| FY2019 | $40.5K | -64.8% |
| FY2018 | $115.2K | +7.1% |
| FY2017 | $107.5K | +87.2% |
| FY2016 | $57.5K | +13.1% |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026